Pfizer Inc.’s Crizotinib Receives Positive Opinion for Conditional Marketing Authorization From the Committee for Medicinal Products for Human Use for the Treatment Of Adults With Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer in the

Published: Jul 20, 2012

NEW YORK--(BUSINESS WIRE)--Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

Back to news